Black Friday: Superpowermembership now $179$199

Methylene Blue and Mitochondria: What Research Shows

Published

Last updated

Key takeaway:

In cell and animal studies, methylene blue acts as an alternative electron carrier in mitochondria, raising Complex IV activity by 30% in one fibroblast line. Human evidence is thin. Two phase 3 trials of the related compound LMTM, including one of 891 adults, missed their primary outcomes. No trial shows a benefit of methylene blue in mitochondrial dysfunction. The FDA label covers acquired methemoglobinemia only.

Read more →

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

What research shows about methylene blue and mitochondria

In cell and animal studies, methylene blue acts as an alternative electron carrier in mitochondria, the main energy producers inside cells. Human studies of methylene blue remain limited, and no clinical trial has shown a benefit for mitochondrial dysfunction.

Methylene blue and mitochondrial peptides are both studied for effects on how cells make and use energy. Mitochondrial-derived peptides, small peptides encoded in mitochondrial DNA, improved insulin sensitivity in rodent studies, and whether they can become human therapies is not yet known. The electron-carrier idea starts with how mitochondria normally pass electrons.

Methylene blue acts as an alternative mitochondrial electron carrier

In cell studies, methylene blue works as an alternative electron carrier, a molecule that moves electrons outside the usual route. Methylene blue cycles between two chemical forms, taking electrons from NADH-using enzymes to become leucomethylene blue. Leucomethylene blue then hands those electrons to cytochrome c, a protein that feeds the chain's final step.

The usual route is the electron transport chain, a series of protein complexes inside mitochondria. NADH and FADH2, electron carriers made as cells break down fuel, donate electrons at Complexes I and II. Electrons then pass through Complex III and cytochrome c to Complex IV. That electron flow drives the production of ATP, the molecule cells run on, and also generates oxidants.

Key results for the electron-cycling model come from one line of human fibroblasts grown in culture. In those cells, methylene blue raised Complex IV activity by 30% and delayed senescence, the point where cells stop dividing. No outcome was measured in a living animal or a person.

Methylene blue's effects also follow a hormetic, or two-phase, dose pattern. Low doses cycle electrons through the chain, while high doses can produce opposite effects.

That lab work also fed Alzheimer's research on tau, a brain protein that forms tangles.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Methylene blue tau research led to the LMTM trials

Laboratory and animal studies of methylene blue and tau led to two phase 3 Alzheimer's trials of LMTM, a related compound. In their randomized comparisons, neither trial showed a benefit on its primary outcomes.

In cell and animal reports, methylene blue reduced plaque and tangle formation and partly restored mitochondrial function. In mice carrying human tau, methylene blue preserved memory in one of two models, and only when started before symptoms.

LMTM, short for leuco-methylthioninium, is a separate compound, a stable reduced form of the molecule in methylene blue. In a 15-month phase 3 trial of 891 adults with mild to moderate Alzheimer's disease, LMTM showed no benefit on thinking or daily function.

A separate 18-month trial of 800 adults found differences only in a revised analysis of non-randomized groups taking LMTM alone. That exploratory result still needs a randomized trial to confirm it.

Smaller human studies took a different approach, imaging the brain after methylene blue itself.

Human imaging studies of methylene blue are small

Human imaging studies of methylene blue gave single doses to small groups and tracked short-term brain changes. None tested lasting effects on memory, and the researchers called for larger studies.

In a placebo-controlled study of 26 healthy adults, one oral dose of methylene blue raised activity in attention and short-term memory regions. One hour later, correct memory-retrieval answers rose 7%. A companion study in 28 healthy adults found stronger resting brain connectivity.

In healthy people and rats, intravenous methylene blue lowered brain blood flow and energy use, contrary to the researchers' expectations. In 42 adults with claustrophobia, methylene blue after exposure therapy had mixed effects on fear one month later.

With human data this thin, most mitochondrial evidence still comes from cell and animal work.

Get 100+ biomarkers tested

One blood draw a year. A full picture of your health, explained in plain language.

Book your test

Methylene blue's mitochondrial evidence remains mostly preclinical

The strongest evidence for methylene blue's mitochondrial effects comes from cell and animal studies. Randomized trials in mitochondrial disorders have found no clear benefit for any intervention. Methylene blue was not among those tested.

In lab experiments, methylene blue routed electrons around blocked steps in the chain and protected cultured neuronal cells. A modified version lacking its electron-carrying site had no effect on the chain. Methylene blue also limited damage in rat models of Parkinson's disease and stroke.

Reviewers have proposed that methylene blue protects cells by supporting Complex IV and heme production, a hypothesis built largely on cell studies. Both processes are impaired in Alzheimer's brains.

Evidence typeWhat existsStatus
Cell and animal studiesElectron carrying, Complex IV support, and protection of neuronal cells against several toxins, though not against direct oxidative stressPreclinical only
Human imagingSingle-dose studies in small groups of healthy adults; short-term changes in brain activity and blood flowPreliminary; no lasting outcome measured
Confirmatory trials of related compounds2 phase 3 LMTM trials missed primary outcomes as randomized; a 2026 phase 3 trial of the same compound, now called hydromethylthionine, found no significant difference on co-primary clinical endpoints at 52 weeksNot confirmed
Use in mitochondrial dysfunctionNo trial showing benefit; most mitochondrial diseases lack a targeted therapy; FDA label covers acquired methemoglobinemia only, with no indication for mitochondrial dysfunction, memory, or Alzheimer's diseaseNone

Until a human trial measures mitochondrial outcomes, methylene blue's effects on mitochondria remain a research question. Methylene blue's known side effects apply to any use of the drug.

IMPORTANT SAFETY INFORMATION

Provayblue carries a boxed warning: methylene blue may cause serious or fatal serotonin syndrome when used with serotonergic drugs and opioids. The label advises avoiding use alongside selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and opioids.

Contraindications on the label: severe hypersensitivity to methylene blue or any other thiazine dye, and glucose-6-phosphate dehydrogenase (G6PD) deficiency, because of the risk of hemolytic anemia. The FDA-approved Provayblue prescribing information is the authoritative label.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

References

  1. Yang L, Youngblood H, Wu C, Zhang Q (2020). Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation. *Transl Neurodegener*, *9*(1), 19. https://doi.org/10.1186/s40035-020-00197-z
  2. Merry TL, Chan A, Woodhead JST, et al (2020). Mitochondrial-derived peptides in energy metabolism. *Am J Physiol Endocrinol Metab*, *319*(4), E659–E666. https://doi.org/10.1152/ajpendo.00249.2020
  3. Atamna H, Nguyen A, Schultz C, et al (2008). Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. *FASEB J*, *22*(3), 703–12. https://doi.org/10.1096/fj.07-9610com
  4. Nolfi-Donegan D, Braganza A, Shiva S (2020). Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement. *Redox Biol*, *37*, 101674. https://doi.org/10.1016/j.redox.2020.101674
  5. Rojas JC, Bruchey AK, Gonzalez-Lima F (2012). Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. *Prog Neurobiol*, *96*(1), 32–45. https://doi.org/10.1016/j.pneurobio.2011.10.007
  6. Wilcock GK, Gauthier S, Frisoni GB, et al (2018). Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. *J Alzheimers Dis*, *61*(1), 435–457. https://doi.org/10.3233/JAD-170560
  7. Oz M, Lorke DE, Petroianu GA (2009). Methylene blue and Alzheimer's disease. *Biochem Pharmacol*, *78*(8), 927–32. https://doi.org/10.1016/j.bcp.2009.04.034
  8. Hochgräfe K, Sydow A, Matenia D, et al (2015). Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. *Acta Neuropathol Commun*, *3*, 25. https://doi.org/10.1186/s40478-015-0204-4
  9. Gauthier S, Feldman HH, Schneider LS, et al (2016). Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. *Lancet*, *388*(10062), 2873–2884. https://doi.org/10.1016/S0140-6736(16)31275-2
  10. Rodriguez P, Singh AP, Malloy KE, et al (2017). Methylene blue modulates functional connectivity in the human brain. *Brain Imaging Behav*, *11*(3), 640–648. https://doi.org/10.1007/s11682-016-9541-6
  11. Rodriguez P, Zhou W, Barrett DW, et al (2016). Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. *Radiology*, *281*(2), 516–526. https://doi.org/10.1148/radiol.2016152893
  12. Singh N, MacNicol E, DiPasquale O, et al (2023). The effects of acute Methylene Blue administration on cerebral blood flow and metabolism in humans and rats. *J Cereb Blood Flow Metab*, *43*(2_suppl), 95–105. https://doi.org/10.1177/0271678X231157958
  13. Telch MJ, Bruchey AK, Rosenfield D, et al (2014). Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. *Am J Psychiatry*, *171*(10), 1091–8. https://doi.org/10.1176/appi.ajp.2014.13101407
  14. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF (2012). Treatment for mitochondrial disorders. *Cochrane Database Syst Rev*, *2012*(4), CD004426. https://doi.org/10.1002/14651858.CD004426.pub3
  15. Wen Y, Li W, Poteet EC, et al (2011). Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. *J Biol Chem*, *286*(18), 16504–15. https://doi.org/10.1074/jbc.M110.208447
  16. Atamna H, Kumar R (2010). Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. *J Alzheimers Dis*, *20 Suppl 2*, S439–52. https://doi.org/10.3233/JAD-2010-100414
  17. Poteet E, Winters A, Yan LJ, et al (2012). Neuroprotective actions of methylene blue and its derivatives. *PLoS One*, *7*(10), e48279. https://doi.org/10.1371/journal.pone.0048279
  18. Wischik CM, Stefanacci R, Bentham P, et al (2026). Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. *J Prev Alzheimers Dis*, *13*(3), 100480. https://doi.org/10.1016/j.tjpad.2026.100480
  19. Ball M, van Bergen NJ, Compton AG, Thorburn DR, Rahman S, Christodoulou J (2025). Therapies for Mitochondrial Disease: Past, Present, and Future. *J Inherit Metab Dis*, *48*(4), e70065. https://doi.org/10.1002/jimd.70065
  20. DailyMed. PROVAYBLUE (methylene blue) injection, prescribing information. US National Library of Medicine. Updated May 2025. Accessed November 11, 2026.

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Biological age 32 — a Superpower member portraitA health system built around you — test, understand, optimize100+ biomarkers across 2 blood drawsWhat to expect with Superpower — week 1 to month 3Better than the status quo — Superpower vs the old way60% of members found something a doctor missed — member survey
Daniel OSuperpower memberDavid LSuperpower memberRachel DSuperpower memberCamelia VSuperpower member

64,000+ members

Superpower health membership

Find early signs of 1,000+ conditions from a single blood draw - then act on what you find.

$199

$179

/year*

Black Friday: $20 off

100+ biomarkers from a single blood draw

Personalized plan that turns results into action

Superpower AI and on-demand care team

Results in 10 days or less

2,000+ labs nationwide

Yearly membership$0.49 / dayHSA/FSA eligible

*Pricing may vary for members in New York and New Jersey

What we test

TestosteroneFree T4Vitamin DApoBHbA1cThyroid (TSH)hs-CRPFerritinCortisolFasting insulin

60%

found something a doctor missed

93%

rated it more useful than their checkup

77%

found something new in their results

Superpower member survey, 90 days post action plan (n=143).

How does the Superpower membership work?

We test 100+ biomarkers from a single blood draw each year. Your baseline test paints a comprehensive picture of your health, and your dashboard shows what’s working, what needs attention, and what to do next. Superpower AI and your care team help you take action across lifestyle, supplements, and treatments.

Can I cancel anytime?

Yes. You can cancel anytime, no fees. Your membership stays active through the end of your paid year.

How often should I test?

Your membership includes two blood tests per year: one to establish your baseline, and one to see whether your plan improved biomarkers that were out of range or not yet optimized. You can add other diagnostics anytime through the app or with help from your care team.

When will I get my results?

Book your draw at any of 2,000+ partner labs. Results are typically ready in about a week and land in the Superpower app.